TME Pharma NV
Company Profile
Business description
TME Pharma NV is a clinical-stage biopharmaceutical company focused on developing novel therapies for treatment of the aggressive cancers and specializing in approaches targeting the tumor microenvironment. Its enhances the effectiveness of cancer treatments including current standards of care (such as antivascular agents, chemotherapy and radiotherapy) and immune-oncology approaches (such as immune checkpoint inhibitors). The company's Spiegelmer platform has generated a proprietary pipeline of clinical-stage product candidates including its cancer drug candidate NOX-A12 and its second clinical-stage asset, NOX-E36, now planned to be developed in eye diseases. The company has one segment active in pioneering the development of a new class of proprietary therapeutics called Spiegelmers.
Contact
Max-Dohrn-Strasse 8-10
Berlin10589
DEUT: +49 30166370820
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
13
Stocks News & Analysis
stocks
Margins have bottomed for ASX listed consumer goods company
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,031.20 | 9.40 | 0.10% |
| CAC 40 | 8,400.11 | 21.03 | -0.25% |
| DAX 40 | 25,139.69 | 153.87 | 0.62% |
| Dow JONES (US) | 51,712.71 | 148.01 | 0.29% |
| FTSE 100 | 10,437.85 | 74.58 | 0.72% |
| HKSE | 23,768.52 | 156.29 | -0.65% |
| NASDAQ | 26,166.60 | 351.33 | -1.32% |
| Nikkei 225 | 72,353.96 | 1,103.90 | 1.55% |
| NZX 50 Index | 13,466.46 | 20.41 | 0.15% |
| S&P 500 | 7,472.79 | 27.79 | -0.37% |
| S&P/ASX 200 | 8,816.10 | 14.20 | 0.16% |
| SSE Composite Index | 4,163.10 | 72.62 | 1.78% |